A 52-year-old woman presents with nasal congestion and an intranasal mass. What is your diagnosis?
Dr. Luis Diaz spoke with Cancer Network about monitoring for residual disease in colon cancer ahead of his presentation at ESMO 2018.
Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.
Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.
In his latest blog, Craig Hildreth explores the terror of the black box warning and how the fear of toxicities affects his patients—and his staff.
In this article, we describe the mechanisms via which interactions between herbs and prescription drugs may occur, and highlight four popular herbs and a medicinal mushroom commonly used by cancer patients, along with reports of their interactions with standard drugs.
An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?
Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making.
This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue
Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.
Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.
This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.
This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.
Avelumab did not improve overall survival compared with docetaxel in patients with PD-L1–positive non–small-cell lung cancer.
When treating low-risk primary basal cell carcinoma (BCC), surgery and external beam radiation yield a better chance of a cure and a lower recurrence rate compared with other treatment modalities.